Tham khảo Teneligliptin

  1. ↑ Kishimoto, M (2013). “Teneligliptin: A DPP-4 inhibitor for the treatment of type 2 diabetes”. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. 6: 187–95. doi:10.2147/DMSO.S35682. PMC 3650886. PMID 23671395.
  2. ↑ “TENELIA® 20mg tablets, a Treatment for Type 2 Diabetes Mellitus Approval of Partial Change in Indication to Lift Restrictions in Combination Therapy - Media & Investors - Daiichi Sankyo”.
  3. ↑ Joanne Bronson; Amelia Black; T. G. Murali Dhar; Bruce A. Ellsworth; J. Robert Merritt (2013). Teneligliptin (Antidiabetic), Chapter: To Market, To Market - 2012. Annual Reports in Medicinal Chemistry. 48. tr. 523–524. doi:10.1016/b978-0-12-417150-3.00028-4. ISBN 9780124171503.
  4. ↑ Nabeno, Mika; Akahoshi, Fumihiko; Kishida, Hiroyuki; Miyaguchi, Ikuko; Tanaka, Yoshihito; Ishii, Shinichi; Kadowaki, Takashi (2013). “A comparative study of the binding modes of recently launched dipeptidyl peptidase IV inhibitors in the active site”. Biochemical and Biophysical Research Communications. 434 (2): 191–196. doi:10.1016/j.bbrc.2013.03.010.

Tài liệu tham khảo

WikiPedia: Teneligliptin http://www.chemspider.com/Chemical-Structure.10123... http://www.daiichisankyo.com/media_investors/media... //pubmed.ncbi.nlm.nih.gov/23671395 //www.ncbi.nlm.nih.gov/pmc/articles/PMC3650886 http://www.commonchemistry.org/ChemicalDetail.aspx... //doi.org/10.1016%2Fb978-0-12-417150-3.00028-4 //doi.org/10.1016%2Fj.bbrc.2013.03.010 //doi.org/10.2147%2FDMSO.S35682 https://chemapps.stolaf.edu/jmol/jmol.php?model=CC... https://pubchem.ncbi.nlm.nih.gov/compound/11949652